Crystal structure of bisoprolol fumarate Form I, (C18H32NO4) (C4H2O4)0.5

被引:1
|
作者
Kaduk, James A. [1 ,2 ]
Gindhart, Amy M. [3 ]
Blanton, Thomas N. [3 ]
机构
[1] IIT, 3101 S Dearborn St, Chicago, IL 60616 USA
[2] North Cent Coll, 131 S Loomis St, Naperville, IL 60540 USA
[3] ICDD, 12 Campus Blvd, Newtown Sq, PA 19073 USA
关键词
bisoprolol fumarate; Zebeta; powder diffraction; Rietveld refinement; density functional theory; DIFFRACTION; VALIDATION; PATTERNS; DENSITY;
D O I
10.1017/S0885715619000757
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The crystal structure of bisoprolol fumarate Form I has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional techniques. Bisoprolol fumarate Form I crystallizes in space group P-1 (#2) with a = 8.165 70(5) angstrom, b = 8.516 39(12) angstrom, c = 16.751 79(18) angstrom, alpha = 89.142(1)degrees, beta = 78.155(1)degrees, gamma = 81.763(1)degrees, V = 1128.265(10) angstrom(3), and Z = 2. The neutral side chain of the bisoprolol cation is probably disordered. The cation and anion are linked by N-H center dot center dot center dot O and O-H center dot center dot center dot O hydrogen bonds. The cations are also linked by N-H center dot center dot center dot O hydrogen bonds. The result is alternating layers of hydrophilic and hydrophobic layers parallel to the ab-plane. The density of the structure is relatively low at 1.130 g cm(-3), but there are no obvious voids in the structure. The powder pattern is included in the Powder Diffraction File (TM) as entry 00-066-1625. (C) 2019 International Centre for Diffraction Data.
引用
收藏
页码:34 / 40
页数:7
相关论文
共 50 条
  • [1] Crystal structure of rivastigmine hydrogen tartrate Form I (Exelon®), C14H23N2O2(C4H5O6)
    Kaduk, James A.
    Zhong, Kai
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2016, 31 (02) : 97 - 103
  • [2] Crystal structure of solifenacin hydrogen succinate, C23H27N2O2(HC4H4O4)
    Kaduk, James A.
    Reid, Joel W.
    Zhong, Kai
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2015, 30 (03) : 211 - 217
  • [3] Crystal structure of pomalidomide Form I, C13H11N3O4
    Kaduk, James A.
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2021, 36 (02) : 114 - 119
  • [4] Crystal structure of lacosamide form I, C13H18N2O3
    Kaduk, James A.
    Zhong, Kai
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2015, 30 (03) : 224 - 230
  • [5] Crystal structure of eltrombopag olamine Form I, (C2H8NO)2 (C25H20N4O4)
    Kaduk, James A.
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2021, 36 (02) : 100 - 106
  • [6] Crystal structure of palbociclib isethionate Form B, (C24H30N7O2)(C2H5O4S)
    Kaduk, James A.
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2021, 36 (03) : 196 - 201
  • [7] Proposed crystal structure of carbadox, C11H10N4O4
    Kaduk, James A.
    Dosen, Anja
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2024, 39 (02) : 82 - 93
  • [8] Crystal structure of ribociclib hydrogen succinate, (C23H31N8O)(HC4H4O4)
    Kaduk, James A.
    Dosen, Anja
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2024, : 227 - 234
  • [9] Crystal structure of sparsentan, C32H40N4O5S
    Kaduk, James A.
    Dosen, Anja
    Blanton, Thomas
    POWDER DIFFRACTION, 2025,
  • [10] Crystal structure of fulvestrant hydrate (ethyl acetate), C32H47F5O3S(H2O)0.16(C4H8O2)0.025
    Kaduk, James A.
    Boaz, Nicholas C.
    Gates-Rector, Stacy D.
    Gindhart, Amy M.
    Blanton, Thomas N.
    POWDER DIFFRACTION, 2022, 37 (03) : 157 - 165